NASDAQ:GRCE

Grace Therapeutics Q4 2025 Earnings Results & Report

Grace Therapeutics logo
$1.71 -0.02 (-1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$1.70 -0.01 (-0.35%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grace Therapeutics beat analyst earnings expectations in its Q4 2025 results, released June 20, 2025. The company reported EPS of -$0.21 versus the -$0.23 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
7:00 AM ET

Grace Therapeutics EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Q4 2025 Earnings FAQ

Grace Therapeutics (NASDAQ:GRCE) reported earnings of -$0.21 per share for Q4 2025, beating the consensus estimate of -$0.23. The report was announced on Friday, June 20, 2025.

Grace Therapeutics Earnings Headlines

I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Grace: Fiscal Q2 earnings snapshot
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) is a clinical-stage biopharmaceutical company developing medicines for rare and orphan diseases. Its drug candidates are designed to address conditions with limited treatment options, including neurological disorders.

The company’s pipeline includes GTX-104, a formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, as well as GTX-102 for ataxia-telangiectasia and GTX-101 for postherpetic neuralgia. These programs use alternative delivery approaches intended to address limitations associated with existing treatments.

Grace Therapeutics was formerly known as Acasti Pharma and adopted its current name as it focused on the development programs associated with Grace Therapeutics. The company’s candidates remain investigational and are not approved medicines.

View Grace Therapeutics Profile